Mandate

Vinge has advised Titania Holding AB (publ) in connection with its listing on Nasdaq First North Growth Market

Vinge has advised Titania Holding AB (publ) (“Titania”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 29 November 2021 and the first day of trading was 10 December 2021.

The price in the offering was SEK 20 per class B share, corresponding to a market capitalization of all of Titania’s shares upon completion of the offering of approximately SEK 1.4 billion.

Titania is a fast-growing real estate company focusing on the Stockholm region. Its operations consist of project development, production and management. Titania participates throughout the entire value chain, from early stages of city and project development to land acquisitions, production and rental and eventually also long-term property management. Titania possesses expertise throughout all steps of the value chain and has capacity to carry out large projects within urban development, adding value in terms of increased social and financial sustainability.

Vinge’s team primarily consisted of David Andersson, Amanda Knutsson, Anna Grigorian and Anna Svensson (Capital Markets and Public M&A), Frida Ställborn (Real Estate), Kamyar Najmi and Benjamin Vafaeian (Banking and Finance).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026